All In Biotech

Drug Trial Radar · NCT05835986

A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus

An Open-label, Multicenter, Dose Escalation, First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered RO7507062 in Participants With Systemic Lupus Erythematosus

Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Dec 18, 2023

Primary completion

Nov 30, 2027

Study completion Nov 30, 2027

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Apr 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of RO7507062 in participants with systemic lupus erythematosus (SLE). The study will have 2 parts: Part 1 is a single ascending dose-finding (SAD) part and Part 2 is a dose escalation with fractionated dosing part.

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • RO7507062Drug

    RO7507062 solution for injection will be administered SC as specified in each treatment part (arm).

  • TocilizumabDrug

    When applicable, tocilizumab solution for infusion will be administered intravenously at 8 milligram per kilogram (mg/kg) for participants \>/= 30 kg or at 12 mg/kg for participants \< 30 kg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants with Dose Limiting Adverse Events (DLAEs)Time frame: Day 1 through Day 29
  2. Part 2: Fractionated Dose Cohort: Number of Participants with DLAEsTime frame: Day 1 through to the end of the 28-day safety evaluation period
  3. Number of Participants with Adverse Events (AEs)Time frame: Up to approximately 12 months

Locations

18 sites in 13 countries. Site status is shown where the registry gives one.

  • Clinica De La Costa

    Barranquilla, Colombia

  • Hospital Pablo Tobon Uribe

    Medellín, Colombia

  • Groupe Hospitalier Pitie-Salpetriere

    Paris, France

  • Charité Research Organisation GmbH

    Berlin, Germany

  • Hospital Umum Sarawak

    Kuching, Malaysia

  • CREA Hospital Mexico Americano

    Guadalajara, Jalisco, Mexico

  • Hospital Angeles De Lindavista

    Mexico City, Mexico CITY (federal District), Mexico

  • Hospital General De Mexico

    Mexico City, Mexico CITY (federal District), Mexico

  • Centre For Human Drug Research

    Leiden, Netherlands

  • Clínica San Juan Bautista CSJB

    Lima, Peru

  • Wojskowy Instytut Medyczny- Panstwowy Instytut Badawczy

    Warsaw, Poland

  • FARMOVS (Pty) Ltd

    Bloemfontein, South Africa

  • Hospital General Universitario Gregorio Marañon

    Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Chung Shan Medical University Hospital

    Taichung, Taiwan

  • Chang Gung Medical Foundation - Linkou

    Taoyuan, Taiwan

  • Ramathibodi Hospital, Mahidol Uni

    Bangkok, Thailand

  • UCL Hospital NHS Trust

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.